2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|May 2, 2005
- Pharmaceutical Technology-05-02-2005
- Volume 29
- Issue 5
High Molecular Weight Polyethylene Oxide-Based Drug Delivery Systems - Part I: Hydrogels and Hydrophilic Matrix Systems
The authors review the solution and powder properties of polyethylene oxide and its various applications in hydrogels and hydrophilic matrix systems.
Advertisement
Articles in this issue
over 21 years ago
New Vaccine Technologies Carry and Deliver by Kaylynn Chiarelloover 21 years ago
GenerationNextover 21 years ago
New Vaccine Technologies Carry and Deliverover 21 years ago
May 2005over 21 years ago
Bar Coding Deadline Loomsover 21 years ago
In the Spotlight - May 2005over 21 years ago
New FDA Policies Shape Pharma Development and Productionover 21 years ago
Automating HPLC and GC Analytical Method Validationover 21 years ago
Price MattersAdvertisement
Related to this article
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Can AI Agents Satisfy CGMP Documentation Requirements?
2
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
3
PharmTech Weekly Roundup—September 18, 2026
4
Introducing the "PharmTech AI Pulse Check" Expert Video Series
5